Docetaxel in the management of patients with head and neck squamous cell carcinoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 7, 2008, Pages 1023-1032

  Bernier, Jacques ^a   Vrieling, Conny ^a  

^a Genolier Swiss Medical Network SA   (Switzerland)

Author keywords

Chemoradiotherapy; Docetaxel; Head and neck; Induction chemotherapy; Larynx preservation; Locally advanced; Metastatic; Recurrent; Squamous cell carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; ANTINEOPLASTIC AGENT; TAXOID;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ASCITES; BURNING SENSATION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE ARREST; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; DESQUAMATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG STRUCTURE; DYSESTHESIA; ERYTHEMA; FEBRILE NEUTROPENIA; FLUID RETENTION; HEAD AND NECK CARCINOMA; HEARING LOSS; HUMAN; INJECTION SITE PAIN; LARYNGECTOMY; LARYNX CANCER; LEUKOPENIA; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA AND VOMITING; NECK DISSECTION; NEUTROPENIA; ONYCHOLYSIS; OVERALL SURVIVAL; PARESTHESIA; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLEURA EFFUSION; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN EDEMA; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; HEAD AND NECK TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; TAXOIDS;

EID: 48849102700     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.7.1023     Document Type: Review

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist 10(3), 215-224 (2005).
3. Pignon JP, le Maître A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. MACH-NC Collaborative Group. Int. J. Radiat. Oncol. Biol. Phys. 69(2 Suppl.), S112-S114 (2007).
4. Bernier J, Bentzen SM. Altered fractionation and combined radio-chemotherapy approaches: pioneering new opportunities in head and neck oncology. Eur. J. Cancer 39(5), 560-571 (2003).
5. Machtay M, Moughan J, Trotti A et al. Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: an RTOG analysis. J. Cli. Oncol. 24(18S) (2006) (Abstract 5500).
6. Decker DA, Drelichman A, Jacobs J et al. Adjuvant chemotherapy with cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in Stage III and IV squamous cell carcinoma of the head and neck. Cancer 51(8), 1353-1355 (1983).
7. The Department of Veterans Affair Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324(24), 1685-1690 (1991).
8. Lefebvre JL, Chevalier D, Luboinski B et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer Phase III trial. EORTC Head and Neck Cancer Cooperative Group. J. Natl. Cancer Inst. 88(13), 890-899 (1996).
9. Paccagnella A, Orlando, Marchiori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J. Natl Cancer Inst. 86(4), 265-272 (1994).
10. Domenge C, Hill C, Lefebvre JL et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). Br. J. Cancer 83(12), 1594-1598 (2000).
11. Hitt R, Grau J, Lopez-Pousa A et al. Phase II/III trial of induction chemotherapy (ICT) with cisplatin/5-fluorouracil (PF) vs. docetaxel (T) plus PF (TPF) followed by chemoradiotherapy (CRT) vs. CRT for unresectable locally advanced head and neck cancer (LAHNC). J. Clin. Oncol. 23(16S) (2005) (Abstract 5578).
12. Schantz SP, Harrison LB, Forastiere A. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: Cancer: Principles and Practice of Oncology. DeVita VT, Hellman SA, Rosenberg SA (Eds). Lippincott Williams & Wilkins, PA, USA 797-860 (2001).
13. Schiff PB, Fant J, Horowitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 277, 665-667 (1979).
14. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr. Cancer Drug Targets (3), 193-203 (2003).
15. Wani MC, Taylor HI, Wall ME. Plant antitumor agents VI. The isolation and structure of taxol: a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93(9), 2325-2327 (1971).
16. Gelmon K. The taxoids: paclitaxel and docetaxel. Lancet 344(8932), 1267-1272 (1994).
17. Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann. Oncol. 5(6), 533-537 (1994).
18. Dreyfuss AI, Clark JR, Norris CM et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 14(5), 1672-1678 (1996).
19. Couteau C, Chouaki N, Leyvraz S et al. A Phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br. J. Cancer 81(3), 457-462 (1999).
20. Guardiola E, Peyrade F, Chaigneau L et al. Results of a randomized Phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur. J. Cancer 40(14), 2071-2076 (2004).
21. Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn. J. Clin. Oncol. 37(7), 477-488 (2007).
22. Monnerat C, Faivre S, Temam S et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann. Oncol. 13(7), 995-1006 (2002).
23. Rooney M, Kish J, Jacobs J et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55(5), 1123-1128 (1985).
24. Colevas AD, Norris CM, Tishler RB et al. A Phase II trial of docetaxell cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J. Clin. Oncol. 17(11), 3503-3511 (1999).
25. Colevas AD, Norris CM, Tishler RB et al. A Phase I/II trial of outpatient docetaxel, cisplatin, 5-fluorouracil, leucovorin (opTPFL) as induction for squamous cell carcinoma of the head and neck (SCCHN). Am. J. Clin. Oncol. 25(2), 153-159 (2002).
26. Posner MR, Glisson B, Frenette G et al. Multicenter Phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J. Clin. Oncol. 19(4), 1096-1104 (2001).
27. Haddad R, Colevas AD, Tishler R et al. Docetaxel, cisplatin and 5-fluorouracil based induction-chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana-Farber Cancer Institute experience. Cancer 97(2), 412-418 (2003).
28. Vermorken JB, Remenar E, van Herpen C et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357(17), 1695-1704 (2007).
29. Posner MR, Hershock DM, Blajman CR et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357(17), 1705-1715 (2007).
30. Haddad R, Tishler R, Wirth L et al. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg. 132(6), 678-681 (2006).
31. Calais G, Pointreau Y, Alfonsi M et al. Induction chemotherapy for larynx preservation. Updated results of the GORTEC 2000-01 randomized trial comparing docetaxel + cisplatinum, + fluorouracil (TPF) versus cisplatinum + fluorouracil (PF). ECCO 14 Meeting, Barcelona, Spain, 23-27 September 2007.
32. Calais G, Bardet E, Sire C et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 GORTEC Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. 58(1), 161-166 (2004).
33. Yoshida T, Tokashiki R, Itoh H et al. A Phase I-II study of bi-weekly docetaxel combined with radiation therapy for patients with cancer of the larynx/hypopharynx. Jpn. J. Clin. Oncol. 37(9), 641-646 (2007).
34. Biete Solà A, Martuecos Querol J, Calvo Manuel FA et al. Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck. Clin. Transl. Oncol. 9(4), 244-250 (2007).
35. Schoffski P, Catimel G, Planting AS et al. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a Phase II study of the EORTC Early Clinical Studies Group. Ann. Oncol. 10(1), 119-122 (1999).
36. Glisson BS, Murphy BA, Frenette G, Khuri FR, Forastiere AA. Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J. Clin. Oncol. 20(6), 1593-1599 (2002).
37. Specht L, Larsen SK, Hansen HS. Phase II study of docetaxel and cisplatin in patients with recurrent or disseminated squamous-cell carcinoma of the head and neck. Ann. Oncol. 11(7), 845-849 (2000).
38. Baur M, Kienzer HR, Schwelger J et al. Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a Phase II trial. Cancer 94(11), 2953-2958 (2002).
39. Guntinas-Lichius O, Appenrodt S, Veelken F, Krug B. Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 116(4), 613-618 (2006).
40. Janinis J, Papadakou M, Xidakis E et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a Phase II feasibility study. Am. J. Clin. Oncol. 23(2), 128-131 (2000).
41. Kim ES, Kies MS, Glisson BS et al. Final results of a Phase II study of erlotinib, docetaxel, and cisplatin in patients with recurrent/ metastatic head and neck cancer (abstract). J. Clin. Oncol. 25(18S), 302s (2007).
42. Bernier J, Remenar E, van Herpen C et al. Impact on quality of life (QoL) of the addition of docetaxel (T) to neoadjuvant cisplatin plus 5-fluorouracil treatment in patients with locally advanced, unresectable squamous cell carcinoma of the head and neck (SCCHN): EORTC study 24971. J. Clin. Oncol. 24(18S), (2006) (Abstract 5522).
43. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349(22), 2091-2098 (2003).
44. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemoradiotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J. Natl Cancer Inst. 91(24), 2081-2086 (1999).
45. Jeremic B, Shibamoto Y, Milicic B et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J. Clin. Oncol. 18(7), 1458-1464 (2000).
46. Denis F, Garaud P, Bardet E et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J. Clin. Oncol. 22(1), 69-76 (2004).
47. Bernier J. Cetuximab in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Nat. Clin. Pract. Oncol. (2008) (In press).